SYRE Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
105.7M
+29.5%
81.6M
+7.9%
75.6M
+32.3%
57.2M
+0.5%
56.9M
R&D
89.2M
+36.1%
65.5M
+8.4%
60.4M
+35.3%
44.6M
-1.3%
45.2M
SG&A
16.6M
+2.6%
16.1M
+5.9%
15.2M
+21.5%
12.5M
+7.7%
11.6M
Operating Income
-105719000
-29.5%
-81639000
-7.9%
-75641000
-32.3%
-57172000
-0.5%
-56888000
EBITDA
-105719000
-29.5%
-81639000
-7.9%
-75641000
-32.3%
-57172000
-0.5%
-56888000
Net Income
-96121000
-165.5%
-36200000
+47.5%
-69005000
-10.4%
-62530000
-459.2%
-11183000
EPS (Basic)
$-0.94
-161.1%
$-0.36
+51.4%
$-0.74
-7.2%
$-0.69
-360.0%
$-0.15
EPS (Diluted)
$-0.94
-161.1%
$-0.36
+51.4%
$-0.74
-7.2%
$-0.69
-360.0%
$-0.15
Shares (Diluted)
88.4M
+4.3%
84.7M
+7.9%
78.5M
+4.4%
75.2M
+24.5%
60.4M
Spyre Therapeutics (SYRE) — Financials